Actively Recruiting
Effect of Sacubitril/Valsartan on Cardiac Function Assessed by Cardiac Magnetic Resonance (CMR) in Hypertensive Patients Stratified by Body Mass Index (BMI): A Real World Study
Led by Beijing Friendship Hospital · Updated on 2025-02-13
180
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate how sacubitril/valsartan affects heart function in patients with high blood pressure, considering their body mass index (BMI). Obesity is known to influence heart structure and function in people with hypertension, and sacubitril/valsartan is viewed as a promising blood pressure medication that may improve heart function. The study compares this medication to other common blood pressure drugs in real-world patients stratified by BMI. The study observes two groups of patients: those already taking sacubitril/valsartan (Entresto) at a dose of 200mg once daily, and those taking other angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACEI/ARB). These other drugs include a variety of medications such as benazepril, captopril, and losartan. Treatments are already ongoing before patients enroll, and the study does not assign new treatments but monitors existing ones. Participants will be assessed over time using cardiac magnetic resonance imaging (CMR) to measure changes in heart function, focusing primarily on left ventricular ejection fraction after six months. Additional measures include heart chamber sizes, systolic function, blood pressure changes, and adverse cardiac events tracked up to 12 months. The study also monitors the effects of hypertension-related organ damage. Participants will undergo periodic evaluations and follow-ups to collect this data throughout the study duration.
CONDITIONS
Brief Title
Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with essential hypertension
- Age between 18 and 70 years
- Able to provide written consent without major barriers
You will not qualify if you...
- Secondary hypertension except due to sleep apnea
- Cardiovascular events (heart attack, heart failure, stroke, or coronary revascularization) within the past 6 months
- Severe diseases such as autoimmune disease, cancer, late-stage liver disease, respiratory disease, or digestive disease
- Unable to understand or follow study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants who are already taking sacubitril/valsartan or ACEI/ARB by prescription are observed to assess cardiac function and blood pressure changes over time.
Visits at 6 months and 12 months
Trial Site Locations
Total: 1 location
1
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100050
Actively Recruiting
Research Team
R
Rongchong Huang, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here